These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 37478396)

  • 1. How I treat non-transfusion-dependent β-thalassemia.
    Saliba AN; Musallam KM; Taher AT
    Blood; 2023 Sep; 142(11):949-960. PubMed ID: 37478396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
    Shash H
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
    Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating iron overload in patients with non-transfusion-dependent thalassemia.
    Taher AT; Viprakasit V; Musallam KM; Cappellini MD
    Am J Hematol; 2013 May; 88(5):409-15. PubMed ID: 23475638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years.
    Musallam KM; Rivella S; Taher AT
    Am J Hematol; 2021 Mar; 96(3):E57-E59. PubMed ID: 33219704
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of non-transfusion-dependent thalassemia: a practical guide.
    Taher AT; Cappellini MD
    Drugs; 2014 Oct; 74(15):1719-29. PubMed ID: 25255924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN; Taher AT
    Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron overload in thalassemia: different organs at different rates.
    Taher AT; Saliba AN
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approach to iron chelation in children.
    Aydinok Y; Kattamis A; Viprakasit V
    Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload in β-thalassemia intermedia: an emerging concern.
    Musallam KM; Cappellini MD; Taher AT
    Curr Opin Hematol; 2013 May; 20(3):187-92. PubMed ID: 23426199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East.
    El-Beshlawy A; Dewedar H; Hindawi S; Alkindi S; Tantawy AA; Yassin MA; Taher AT
    Blood Rev; 2024 Jan; 63():101138. PubMed ID: 37867006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.
    Sleiman J; Tarhini A; Bou-Fakhredin R; Saliba AN; Cappellini MD; Taher AT
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalassemia Intermedia: Chelator or Not?
    Lee YC; Yen CT; Lee YL; Chen RJ
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.
    Bou-Fakhredin R; Bazarbachi AH; Chaya B; Sleiman J; Cappellini MD; Taher AT
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Αlpha-thalassemia: A practical overview.
    Musallam KM; Cappellini MD; Coates TD; Kuo KHM; Al-Samkari H; Sheth S; Viprakasit V; Taher AT
    Blood Rev; 2024 Mar; 64():101165. PubMed ID: 38182489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management.
    Vichinsky E
    Curr Med Res Opin; 2016; 32(1):191-204. PubMed ID: 26479125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2021 update on clinical trials in β-thalassemia.
    Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
    Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT; Temraz S; Cappellini MD
    Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.